Key facts
- It has raised $3.0M; the latest was Early Stage VC ($3.0M) in Apr 2026.
- Notable investors include Charles Songhurst, Point Nine Capital, Amino Collective, Common Magic, Emerge (London) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Equator
- ·The full record, as it builds
Funding rounds
No funding rounds for Equator are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Equator
Developer of an AI-powered platform designed to deliver domain-specific intelligence for biopharma launch execution. The company's platform includes features such as knowledge centralization, agentic AI workflows, modular natural-language assistants, and compliant system integrations, enabling biopharma organizations to automate repetitive tasks, improve collaboration, streamline launch operations, and improve time-to-value.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- eqtr.ai/
- Ownership
- Privately Held (backing)
Equator doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Equator shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Equator in its N-PORT filings yet. We sweep new filings monthly.